Audley Reid CEO R.A. Williams Distributors Limited has released the following unaudited financial results for the third quarter ended January 31, 2025, prepared in accordance with IFRS Accounting Standards.
FINANCIAL PERFORMANCE
Revenues for the quarter totalled $438.9 million, up from $380.8 million in the same period last year, demonstrating sustained strong demand for our products. However, the Company experienced an 8% decline in gross profit margin, which stood at 46% for the quarter, primarily due to lower margins on government sales. The net profit margin after tax was 3%, compared to 16% in the prior year, demonstrating our ability to maintain profitability despite market challenges.
Operating expenses as a percentage of revenue increased to 40%, up from 33% in the previous year, mainly due to increased costs related to the right-of-use for our New Brunswick Village location, depreciation on acquired assets, and higher staffing and distribution expenses. Additionally, total assets grew by 56% year-over-year, signalling a positive trajectory and reflecting the ongoing progress of our strategic initiatives as we continue to execute them over the medium to long term.
PRODUCT LAUNCHES AND MARKET EXPANSION
This quarter marked a significant milestone with the official launch of Iracet (Levetiracetam 500 mg), a key addition to our product portfolio. As the first generic of its kind on the Jamaican market, this antiepileptic drug has received a positive response from the medical community. By the end of the quarter, Iracet was also made available at National Health Fund’s Drug-Serv Pharmacies, greatly expanding access for patients. This marks a major achievement in our mission to improve patient outcomes through affordable and accessible medications. In addition to Iracet, we introduced several products under our partnership with Fourrts. These include Cofex, an over-the-counter cough and cold remedy, as well as Sucrafil and Sucrafil-O, prescription medications used in the treatment of stomach ulcers and hyperacidity. These additions further strengthen our diverse product offering and position us to meet the growing needs of the healthcare market.
Furthermore, our Ryvis product line, launched in May 2024, continues to gain momentum. We are excited to announce the upcoming addition of 21 prescription drugs, spanning areas such as pain management, gastrointestinal health, cardiovascular care, and antibacterial treatments. This expansion enhances our market position and supports our strategy to provide comprehensive healthcare solutions for patients and healthcare providers.
OUTLOOK
As we continue to expand our product portfolio and strengthen our market presence, we remain focused on delivering value to our stakeholders. We are confident in our ability to navigate the evolving healthcare landscape, leveraging our diverse offerings and strong industry partnerships. We look forward to building on our successes in the coming quarters and achieving sustained growth.
Audley Reid CEO R.A. Williams Distributors Limited
For More Information CLICK HERE
